GTx Incorporated
Public | |
Traded as | NASDAQ: GTXI |
Industry | Pharmaceuticals |
Founded | September 24, 1997 |
Headquarters | Memphis, Tennessee, United States |
Products | Toremifene, Ostarine, Andarine |
Website | GTxInc.com |
GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways.[1] Its major product to date is toremifene, and drugs in development include enobosarm (ostarine) and GTx-758. The company has undertaken partnerships with other biotechnology companies such as Merck[2] in the development of drugs in the selective estrogen receptor modulator (SERM) and selective androgen receptor modulator (SARM) classes.
References
- ↑ "About GTx". Retrieved May 17, 2011.
- ↑ "GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting". Retrieved May 17, 2011.
This article is issued from Wikipedia - version of the 9/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.